Literature DB >> 27536180

Cost-effectiveness of pazopanib: an example of improved transparency and accessibility of industry-sponsored economic evaluations through publication in peer-reviewed journals.

J Beca1, K K W Chan2.   

Abstract

Entities:  

Year:  2016        PMID： 27536180      PMCID： PMC4974037          DOI： 10.3747/co.22.2741

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  10 in total

1.  Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.

Authors:  Bernard Escudier; Camillo Porta; Petri Bono; Thomas Powles; Tim Eisen; Cora N Sternberg; Jürgen E Gschwend; Ugo De Giorgi; Omi Parikh; Robert Hawkins; Emmanuel Sevin; Sylvie Négrier; Sadya Khan; Jose Diaz; Suman Redhu; Faisal Mehmud; David Cella
Journal:  J Clin Oncol       Date:  2014-03-31       Impact factor: 44.544

Review 2.  Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D.

Authors:  Stephen J Walters; John E Brazier
Journal:  Qual Life Res       Date:  2005-08       Impact factor: 4.147

3.  Publication patterns of cancer cost-effectiveness studies presented at major conferences.

Authors:  K K Chan; E Siu; L Mozessohn; M C Cheung
Journal:  Curr Oncol       Date:  2013-12       Impact factor: 3.677

4.  Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility: A Bayesian Approach.

Authors:  Eleanor M Pullenayegum; Kelvin K W Chan; Feng Xie
Journal:  Med Decis Making       Date:  2015-07-02       Impact factor: 2.583

5.  How to interpret patient preferences in selecting the best drug: are the current measurements up to the job?

Authors:  Marc B Garnick
Journal:  J Clin Oncol       Date:  2014-03-31       Impact factor: 44.544

6.  Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.

Authors:  Robert J Motzer; Thomas E Hutson; Lauren McCann; Keith Deen; Toni K Choueiri
Journal:  N Engl J Med       Date:  2014-05-01       Impact factor: 91.245

7.  Underestimation of Variance of Predicted Health Utilities Derived from Multiattribute Utility Instruments.

Authors:  Kelvin K W Chan; Feng Xie; Andrew R Willan; Eleanor M Pullenayegum
Journal:  Med Decis Making       Date:  2016-07-10       Impact factor: 2.583

8.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; David Cella; James Reeves; Robert Hawkins; Jun Guo; Paul Nathan; Michael Staehler; Paul de Souza; Jaime R Merchan; Ekaterini Boleti; Kate Fife; Jie Jin; Robert Jones; Hirotsugu Uemura; Ugo De Giorgi; Ulrika Harmenberg; Jinwan Wang; Cora N Sternberg; Keith Deen; Lauren McCann; Michelle D Hackshaw; Rocco Crescenzo; Lini N Pandite; Toni K Choueiri
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

9.  Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.

Authors:  Cora N Sternberg; Ian D Davis; Jozef Mardiak; Cezary Szczylik; Eunsik Lee; John Wagstaff; Carlos H Barrios; Pamela Salman; Oleg A Gladkov; Alexander Kavina; Juan J Zarbá; Mei Chen; Lauren McCann; Lini Pandite; Debasish F Roychowdhury; Robert E Hawkins
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

10.  Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer.

Authors:  A Simon Pickard; Maureen P Neary; David Cella
Journal:  Health Qual Life Outcomes       Date:  2007-12-21       Impact factor: 3.186
  10 in total
  1 in total

1.  Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review.

Authors:  Carlos E Rodriguez-Martinez; Monica P Sossa-Briceño; Jose A Castro-Rodriguez
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.